DIRAS3: Potential Drug Target Or Biomarker for Various Diseases

Target Name: DIRAS3

NCBI ID: G9077

DIRAS3

DIRAS3: Potential Drug Target Or Biomarker for Various Diseases

The DIRAS3 gene is a member of the RAS (Ras-associated protein of 30kDa) gene family, which is a well-known group of genes that are involved in various signaling pathways in the cell. The RAS gene family plays a crucial role in the regulation of cell growth, differentiation, and survival, and is implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

DIRAS3 is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and regulation are still being studied, but its potential as a drug target is based on its involvement in several key signaling pathways.

One of the well-established functions of the RAS gene family is the regulation of cell growth and differentiation. The RAS/MAPK pathway is a critical signaling pathway that regulates the growth and survival of cancer cells, and is implicated in the development of many types of cancer. The DIRAS3 gene is known to be involved in this pathway, and studies have suggested that it may play a role in the regulation of cell growth and differentiation.

Another key function of the RAS gene family is the regulation of the immune response. The RAS/MAPK pathway has been shown to play a role in the regulation of immune cell function and their output. DIRAS3 is involved in this pathway and its expression has been shown to be regulated by factors such as TGF-β, NF-kappa-B and NF-IL-1.

DIRAS3 is also involved in the regulation of cell survival and has been shown to play a role in the regulation of cell apoptosis. The DIRAS3 gene has been shown to encode a protein that is involved in cell apoptosis, and studies have suggested that it may be a potential drug target for neurodegenerative diseases.

In addition to its involvement in cell growth, differentiation, and survival, the DIRAS3 gene is also involved in the regulation of inflammation. The RAS gene family has been shown to play a role in the regulation of inflammatory responses, and DIRAS3 is no exception. Studies have shown that DIRAS3 is involved in the regulation of pro-inflammatory cytokine production and the expression of immune cell functions, such as the production of antibodies.

DIRAS3 is also a potential biomarker for some diseases, as its expression has been shown to be regulated by a variety of factors, including TGF-β, NF-kappa-B, and NF-IL-1. This suggests that it may be a useful biomarker for the diagnosis and monitoring of certain types of cancer, neurodegenerative diseases and autoimmune disorders.

In conclusion, the DIRAS3 gene is a member of the RAS gene family that is involved in various signaling pathways that are crucial for cell growth, differentiation, and survival. Its potential as a drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for further research. Further studies are needed to fully understand its function and regulation, and to determine its potential as a drug or biomarker.

Protein Name: DIRAS Family GTPase 3

The "DIRAS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DIRAS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets